Abstract：
UNASSIGNED: Most therapeutics delivered using short-acting formulations need repeated administration, which can harm patient compliance and raise failure risks related to inconsistent treatment. Injectable long-acting formulations (ILAFs) are controlled/sustained-release formulations fabricated to deliver active pharmaceutical ingredients (APIs) and extend their half-life over days to months. Longer half-lives of ILAFs minimize the necessity for frequent doses, increase patient compliance, and reduce the risk of side effects from intravenous (IV) infusions. Using ILAF technologies, the immediate drug release can also be controlled, thereby minimizing potential adverse effects due to high initial drug blood concentrations.
UNASSIGNED: In this review, we have discussed various ILAFs, their physiochemical properties, fabrication technologies, advantages, and practical issues, as well as address some major challenges in their application. Especially, the approved ILAFs are highlighted.
UNASSIGNED: ILAFs are sustained-release formulations with extended activity, which can improve patient compliance. ILAFs are designed to deliver APIs like proteins and peptides and extend their half-life over days to months. The specific properties of each ILAF preparation, such as extended-release and improved drug targeting capabilities, make them an effective approach for precise and focused therapy. Furthermore, this is especially helpful for biopharmaceuticals with short biological half-lives and low stability since most environmental conditions can protect them from sustained-release delivery methods.
UNASSIGNED: In this review, we have discussed various ILAFs, their physiochemical properties, fabrication technologies, advantages, and practical issues, as well as address some major challenges in their application. Especially, the approved ILAFs are highlighted.
UNASSIGNED: ILAFs are sustained-release formulations with extended activity, which can improve patient compliance. ILAFs are designed to deliver APIs like proteins and peptides and extend their half-life over days to months. The specific properties of each ILAF preparation, such as extended-release and improved drug targeting capabilities, make them an effective approach for precise and focused therapy. Furthermore, this is especially helpful for biopharmaceuticals with short biological half-lives and low stability since most environmental conditions can protect them from sustained-release delivery methods.
摘要：
■使用短效制剂递送的大多数治疗剂需要重复给药，这可能会损害患者的依从性，并增加与治疗不一致相关的失败风险。可注射长效制剂(ILAF)是被制造以递送活性药物成分(API)并将其半衰期延长数天至数月的受控/持续释放制剂。较长的半衰期的ILAFs最小化频繁剂量的必要性，提高患者依从性，并降低静脉（IV）输注副作用的风险。使用ILAF技术，也可以控制药物的即时释放，从而最大限度地减少由于高初始药物血液浓度引起的潜在不良反应。
■在这篇评论中，我们已经讨论了各种ILAFs，它们的生理化学性质，制造技术，优势,和实际问题，以及解决其应用中的一些主要挑战。尤其是,已批准的ILAF突出显示。
■ILAF是具有延长活性的缓释制剂，这可以提高患者的依从性。ILAFs旨在提供蛋白质和肽等API，并将其半衰期延长数天至数月。每种ILAF制剂的特定性质，例如延长释放和改善药物靶向能力，使它们成为精确和集中治疗的有效方法。此外，这对于生物半衰期短且稳定性低的生物制药尤其有用,因为大多数环境条件可以保护它们免受持续释放给药方法的影响.
■在这篇评论中，我们已经讨论了各种ILAFs，它们的生理化学性质，制造技术，优势,和实际问题，以及解决其应用中的一些主要挑战。尤其是,已批准的ILAF突出显示。
■ILAF是具有延长活性的缓释制剂，这可以提高患者的依从性。ILAFs旨在提供蛋白质和肽等API，并将其半衰期延长数天至数月。每种ILAF制剂的特定性质，例如延长释放和改善药物靶向能力，使它们成为精确和集中治疗的有效方法。此外，这对于生物半衰期短且稳定性低的生物制药尤其有用,因为大多数环境条件可以保护它们免受持续释放给药方法的影响.
